Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Persistence of HIV in Gut‐Associated Lymphoid Tissue despite Long‐Term Antiretroviral Therapy

(2008) Tae‐Wook Chun et al.   JOURNAL OF INFECTIOUS DISEASES

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA